OTCMKTS:NGENF NervGen Pharma (NGENF) Stock Price, News & Analysis $5.84 0.00 (0.00%) As of 11/10/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartNews and TrendsSEC Filings About NervGen Pharma Stock (OTCMKTS:NGENF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NervGen Pharma alerts:Sign Up Key Stats Today's Range$5.84▼$5.8450-Day Range$5.84▼$5.8452-Week Range$1.50▼$6.10VolumeN/AAverage Volume134,507 shsMarket Capitalization$360.74 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing treatments that promote the repair and recovery of the nervous system. The company is headquartered in Vancouver, British Columbia, and conducts research and clinical development activities in North America. NervGen’s lead product candidate is NVG-291, an investigational therapeutic peptide designed to enhance neural repair by modulating the activity of protein tyrosine phosphatase sigma, a molecular target associated with impaired regeneration after nervous-system injury. The company is evaluating NVG-291 for conditions including spinal cord injury and multiple sclerosis, with additional potential applications in other neurological disorders. NervGen’s development programs are centered on translating laboratory research into treatments for people with limited recovery options following damage to the central or peripheral nervous system. Its programs remain investigational, and the safety and effectiveness of NVG-291 have not been established for commercial use.AI Generated. May Contain Errors. Read More Receive NGENF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NervGen Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NGENF Stock News HeadlinesHC Wainwright & Co. initiates coverage of NervGen Pharma (NGEN) with buy recommendationApril 28, 2026 | msn.comNervGen beruft Keith Vendola zum neuen FinanzvorstandApril 27, 2026 | de.investing.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 11 at 1:00 AM | Profits Run (Ad)NervGen Pharma Names Keith Vendola Chief Financial OfficerApril 27, 2026 | marketwatch.comNervGen Pharma Corp.: NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial OfficerApril 27, 2026 | finanznachrichten.deNervGen Pharma to Participate in the H.C. Wainwright ‘HCW@Home’ Series and the 2026 Bloom Burton & Co. Healthcare Investor ConferenceApril 13, 2026 | financialpost.comFAnalysts Offer Insights on Healthcare Companies: Milestone Scientific (MLSS) and NervGen Pharma (NGEN)April 10, 2026 | theglobeandmail.comNervGen: FDA stimmt zulassungsrelevanter Phase-3-Studie für Tetraplegie-Medikament zuApril 7, 2026 | de.investing.comSee More Headlines NGENF Stock Analysis - Frequently Asked Questions How have NGENF shares performed this year? NervGen Pharma's stock was trading at $5.60 on January 1st, 2026. Since then, NGENF shares have increased by 4.3% and is now trading at $5.84. How do I buy shares of NervGen Pharma? Shares of NGENF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NervGen Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that NervGen Pharma investors own include Palantir Technologies (PLTR), Medicenna Therapeutics (MDNA), BBVA Banco Frances (BBAR), KULR Technology Group (KULR), Achieve Life Sciences (ACHV), Acurx Pharmaceuticals (ACXP) and Capricor Therapeutics (CAPR). Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:NGENF CIK1751912 Webwww.nervgen.com Phone(778) 731-1711FaxN/AEmployees7Year Founded2017Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.07 million Net MarginsN/A Pretax MarginN/A Return on Equity-73.14% Return on Assets-56.59% Debt Debt-to-Equity Ratio0.04 Current Ratio11.21 Quick Ratio11.21 Sales & Book Value Annual Sales$150 thousand Price / Sales2,404.91 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares61,770,000Free FloatN/AMarket Cap$360.74 million OptionableNot Optionable BetaN/A Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (OTCMKTS:NGENF) was last updated on 11/10/2026 by MarketBeat.com Staff. From Our PartnersHas The AI Bubble Popped?A recent sell-off wiped $2.3 trillion off the Nasdaq 100 in a single day, leaving Wall Street split on whether...Porter & Company | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NervGen Pharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share NervGen Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NGENF Stock Alerts